Alpelisib plus fulvestrant in PIK3CA-Altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial by Juric, D, Janku, F, Rodón, J, Burris, H, Mayer, I, Schuler, M, Seggewiss-Bernhardt, R, Gil-Martin, M, Middleton, M, Baselga, J, Bootle, D, Demanse, D, Blumenstein, L, Schumacher, K, Huang, A, Quadt, C, Rugo, H